TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28187739

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) assessment for cardiomyopathy (21%)
Number of subjects: 62456

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) assessment for myocardial viability (16%)
Number of subjects: 62456

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) stress perfusion for chest pain syndromes (16%)
Number of subjects: 62456

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) evaluation of etiology of arrhythmias or planning of electrophysiological studies (15%)
Number of subjects: 62456

Group type: EXPERIMENTAL
Intervention: Use of gadolinium-based contrast media in CMR studies (95%)
Number of subjects: 62456
Study: 28187747

Group type: EXPERIMENTAL
Intervention: Comprehensive Primary Care (CPC) initiative
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CFIR framework
Number of subjects: 21
Study: 28187771

Group type: EXPERIMENTAL
Intervention: Estradiol (E)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FSH stimulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chronic, unopposed E
Number of subjects: 9
Study: 28187933

Group type: EXPERIMENTAL
Intervention: Abdominal bioimpedance (BIA) with the ViScan device
Number of subjects: 140

Group type: COMPARATOR
Intervention: CT (computed tomography)
Number of subjects: 140
Study: 28188000

Group type: EXPERIMENTAL
Intervention: Structured program for β-blocker titration with up-titration visits every 2 weeks after implantation (target dose: 10mg/day of bisoprolol or 50mg/day of carvedilol).
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Remote monitoring for 66 patients in Study Group with daily transmission of weight and blood pressure data.
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard practice of the centers (Control Group).
Number of subjects: 254
Study: 28188235

Group type: EXPERIMENTAL
Intervention: Cannabis edibles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Draeger DrugTest
Number of subjects: 0
Study: 28188239

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 326

Group type: COMPARATOR
Intervention: No immunosuppressant
Number of subjects: 326
Study: 28188334

Group type: EXPERIMENTAL
Intervention: AICAR
Number of subjects: 2
Study: 28188472

Group type: EXPERIMENTAL
Intervention: Maternal PPD and CMP
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Maternal CMP only
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Maternal PPD only
Number of subjects: 473

Group type: COMPARATOR
Intervention: No maternal depression
Number of subjects: 473
Study: 28188565

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Lithium and Quetiapine (both interventions)
Number of subjects: 482
Study: 28188773

Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine administration
Number of subjects: 49
Study: 28188907

Group type: EXPERIMENTAL
Intervention: NEO6860 (TRPV1 antagonist)
Number of subjects: 64
Study: 28189300

Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Macular pigment optical density (MPOD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Central adiposity
Number of subjects: 40
Study: 28190158

Group type: EXPERIMENTAL
Intervention: Ketamine mouthwash 20 mg/5 mL four times daily
Number of subjects: 30
Study: 28190704

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (photon radiation therapy)
Number of subjects: 76
Study: 28190716

Group type: EXPERIMENTAL
Intervention: Aorfix endograft (for highly angulated necks)
Number of subjects: 218
Study: 28191026

Group type: EXPERIMENTAL
Intervention: 5 g Flaxseed Fiber (FF) with Orlistat
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1200 mg Dairy Calcium (Ca) with Orlistat
Number of subjects: 38

Group type: COMPARATOR
Intervention: Orlistat alone
Number of subjects: 38
Study: 28191034

Group type: EXPERIMENTAL
Intervention: Integrated treatments plus a once-daily multivitamin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Multivitamin alone (waiting list group)
Number of subjects: 34
Study: 28191263

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Relaxation as a coping strategy
Number of subjects: 158
Study: 28192114

Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine (200 mg twice a day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine (400 mg twice a day)
Number of subjects: 14
Study: 28192597

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg orally and daily on a continuous schedule)
Number of subjects: 19
Study: 28193179

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (SMK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moist snuff consumption (MSC)
Number of subjects: 0
Study: 28193194

Group type: EXPERIMENTAL
Intervention: Accelerometer-assessed physical activity and sedentary behavior
Number of subjects: 7048

Group type: EXPERIMENTAL
Intervention: Falls surveillance with monthly calendars and telephone interviews
Number of subjects: 7048

Group type: EXPERIMENTAL
Intervention: Adjudication of incident cardiovascular disease (CVD) events
Number of subjects: 7048
Study: 28193515

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 5766

Group type: COMPARATOR
Intervention: Not exposed to biologics (Control)
Number of subjects: 5766
Study: 28193518

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir 50 mg/100 mg once daily for 12 weeks
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir 50 mg/100 mg once daily for 12 weeks with ribavirin
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir with ribavirin for 16 or 18 weeks
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir without ribavirin for 16 or 18 weeks
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir for 12 weeks in patients with HCV genotype 1a with baseline RASs
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir for 12 weeks in patients with HCV genotype 1a without baseline RASs
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir and ribavirin for 16 or 18 weeks in patients with HCV genotype 1a with baseline RASs
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir
Number of subjects: 402
Study: 28193647

Group type: EXPERIMENTAL
Intervention: 2-day dihydroartemisinin-piperaquine (2DP) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-day dihydroartemisinin-piperaquine (3DP) regimen
Number of subjects: 0
Study: 28193678

Group type: EXPERIMENTAL
Intervention: Aspirin desensitization protocol (5.5 hours)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Aspirin desensitization protocol
Number of subjects: 330
Study: 28193677

Group type: EXPERIMENTAL
Intervention: High Platelet Reactivity (HPR) on clopidogrel (P2Y12 reactivity units >208) in women
Number of subjects: 8448

Group type: EXPERIMENTAL
Intervention: High Platelet Reactivity (HPR) on clopidogrel (P2Y12 reactivity units >208) in men
Number of subjects: 8448
Study: 28193704

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28193717

Group type: EXPERIMENTAL
Intervention: Familial dilated cardiomyopathy (FDCM)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Idiopathic dilated cardiomyopathy (IDCM)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Combined end point of death or transplantation
Number of subjects: 870
Study: 28194012

Group type: EXPERIMENTAL
Intervention: Methylation levels at the cg07814318 site within the KLF13 gene
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methylation levels at the cg07814318 site
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Expression of KLF13
Number of subjects: 23
Study: 28194229

Group type: EXPERIMENTAL
Intervention: MiR-Test scores
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Free circulating DNA
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sputum biomarkers
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Somatic mutations in tumours
Number of subjects: 202
Study: 28194232

Group type: EXPERIMENTAL
Intervention: Post-challenge OGTT 2 h insulin in CSX
Number of subjects: 237

Group type: COMPARATOR
Intervention: Post-challenge OGTT 2 h insulin in CAD
Number of subjects: 237

Group type: COMPARATOR
Intervention: Metabolically unhealthy obesity in CAD
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Fasting glucose, insulin, HOMA-IR in CSX
Number of subjects: 237

Group type: COMPARATOR
Intervention: Fasting glucose, insulin, HOMA-IR in CAD
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Matsuda index in CSX
Number of subjects: 237

Group type: COMPARATOR
Intervention: Matsuda index in CAD
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: HbA1c in CSX
Number of subjects: 237

Group type: COMPARATOR
Intervention: HbA1c in CAD
Number of subjects: 237
Study: 28194281

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact between father and newborn
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 83
Study: 28194306

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) plus integrated program (IP)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Integrated program (IP) alone
Number of subjects: 131
Study: 28194539

Group type: EXPERIMENTAL
Intervention: Pimasertib (45 mg/day) plus Temsirolimus (25 mg/week)
Number of subjects: 33
Study: 28196056

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX; Ozurdex 700 μg) administered immediately after cataract surgery
Number of subjects: 24
Study: 28196257

Group type: EXPERIMENTAL
Intervention: Scalp cooling system
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no scalp cooling)
Number of subjects: 122
Study: 28196270

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly
Number of subjects: 64
Study: 28196343

Group type: EXPERIMENTAL
Intervention: Abused children
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (non-abused children)
Number of subjects: 78
Study: 28196509

Group type: EXPERIMENTAL
Intervention: Hemochron® Signature POCT for PT/INR and ACT+
Number of subjects: 68

Group type: COMPARATOR
Intervention: Laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity
Number of subjects: 68
Study: 28196715

Group type: EXPERIMENTAL
Intervention: Killed oral cholera vaccine (OCV), Shanchol™
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (non-exposed to OCV)
Number of subjects: 138
Study: 28196730

Group type: EXPERIMENTAL
Intervention: Contact Lens (CL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intraocular Lens (IOL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Additional surgery to clear visual axis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 70
Study: 28196818

Group type: EXPERIMENTAL
Intervention: Morning hypertension without nocturnal hypertension (subtype II)
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Morning hypertension with nocturnal hypertension (subtype III)
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Morning normotension (subtype I)
Number of subjects: 1070
Study: 28196905

Group type: EXPERIMENTAL
Intervention: DHP107, a novel oral paclitaxel formulation, 200 mg/m
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DHP107, a novel oral paclitaxel formulation, 150-250 mg/m
Number of subjects: 17
Study: 28196961

Group type: EXPERIMENTAL
Intervention: Bronchoscopic sampling (protected specimen brushings and bronchoalveolar lavages)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavages (BAL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Protected specimen brushings (PSB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bronchoscope contamination control specimens
Number of subjects: 8
Study: 28197031

Group type: EXPERIMENTAL
Intervention: 75 mg oral diclofenac 1 hour before procedure (Group A)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 121
Study: 28197834

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study: 28197843

Group type: EXPERIMENTAL
Intervention: Copeptin measurement upon presentation to the emergency department
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Copeptin measurement after adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Copeptin measurement in relation to the multivariate logistic clinical model
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Copeptin values in patients reaching the secondary endpoint
Number of subjects: 391
Study: 28197931

Group type: COMPARATOR
Intervention: LSD 100 µg
Number of subjects: 40

Group type: COMPARATOR
Intervention: LSD 200 µg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LSD 100 µg and 200 µg
Number of subjects: 40
Study: 28197979

Group type: EXPERIMENTAL
Intervention: OM3-CA 4 g once daily from day 8 to day 28
Number of subjects: 78

Group type: COMPARATOR
Intervention: OM3-CA 4 g
Number of subjects: 78

Group type: COMPARATOR
Intervention: Simvastatin 40 mg plus ASA 81 mg once daily for 14 days
Number of subjects: 78
Study: 28199472

Group type: EXPERIMENTAL
Intervention: Rare RAAS variants
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Rare APLN variants
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Minor allele of rs78377269
Number of subjects: 600
Study: 28199478

Group type: EXPERIMENTAL
Intervention: Topical carmustine and intravenous O6-benzylguanine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dual-dose O6-benzylguanine plus carmustine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single-dose O6-benzylguanine and carmustine
Number of subjects: 17
Study: 28199523

Group type: EXPERIMENTAL
Intervention: Preoperative cerebral microemboli (ME)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative cerebral microemboli (ME)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative solid ME
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative solid ME
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cerebral blood flow velocity (CBFV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygen index
Number of subjects: 50
Study: 28199816

Group type: EXPERIMENTAL
Intervention: Epoch 1 (2000-2003)
Number of subjects: 4458
Study: 28199907

Group type: EXPERIMENTAL
Intervention: Perceived genetic influences on eating behavior
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Genetic attributions for eating behaviors
Number of subjects: 261
Study: 28202056

Group type: EXPERIMENTAL
Intervention: 400 ml 12.6% carbohydrate-rich drink
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gender-matched reference group (elective hip replacement patients)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gender-matched reference group (healthy volunteers)
Number of subjects: 9
Study: 28202638

Group type: EXPERIMENTAL
Intervention: Single-Dose Supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian Rhythm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time within Feed
Number of subjects: 0
Study: 28202705

Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention for tics (CBIT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Number of subjects: 248
Study: 28203424

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with paclitaxel and cisplatin plus McKeown esophagectomy with total two-field lymphadenectomy
Number of subjects: 528

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 528
Study: 28203475

Group type: EXPERIMENTAL
Intervention: Chin-Down Maneuver
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28203689

Group type: EXPERIMENTAL
Intervention: Day-to-day SBP variability parameters (SD, CV, Δ SBP)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Day-to-day Δ SBP
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Day-to-day Δ SBP (after adjusting for mean SBP)
Number of subjects: 229
Study: 28204448

Group type: EXPERIMENTAL
Intervention: CMR measured myocardial perfusion reserve (MPR)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise testing (ETT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MPR
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 174
Study: 28204544

Group type: EXPERIMENTAL
Intervention: 99mTc-tilmanocept
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-HIV-infected subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 2
Study: 28204726

Group type: EXPERIMENTAL
Intervention: Qutenza® (topical capsaicin 8%)
Number of subjects: 20
Study: 28205030

Group type: EXPERIMENTAL
Intervention: Reduced-port robotic distal gastrectomy (RRDG)
Number of subjects: 19
Study: 28205038

Group type: EXPERIMENTAL
Intervention: Loxapine for inhalation
Number of subjects: 0
Study: 28205039

Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) (0.2 U/kg)
Number of subjects: 218
Study: 28205231

Group type: EXPERIMENTAL
Intervention: ctDNA detection in plasma samples from metastatic pancreatic cancer patients
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: ctDNA presence monitoring after chemotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: ERBB2 exon17 mutation
Number of subjects: 188
Study: 28207430

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre with manual holding of the rebreathing bag and constant airway pressure of 30 cmH2O for 10 s before fluid loading
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baseline PPVauto
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baseline PPVmanual
Number of subjects: 49

Group type: COMPARATOR
Intervention: Central venous pressure
Number of subjects: 49
Study: 28207791

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations of 40 to 49.99 nmol/L
Number of subjects: 26916

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations of 30 to 39.99 nmol/L
Number of subjects: 26916

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations of <30 nmol/L
Number of subjects: 26916

Group type: COMPARATOR
Intervention: 25(OH)D concentrations of 75 to 99.99 nmol/L
Number of subjects: 26916

Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality
Number of subjects: 26916

Group type: EXPERIMENTAL
Intervention: Cancer mortality
Number of subjects: 26916

Group type: EXPERIMENTAL
Intervention: High 25(OH)D levels up to 125 nmol/L
Number of subjects: 26916
Study: 28207896

Group type: EXPERIMENTAL
Intervention: Granzyme A-/- mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granzyme K-/- mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granzyme B-/- mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with Serpinb6b (granzyme A inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-human primates post CHIKV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small cohort of human CHIKV patients
Number of subjects: 0
Study: 28209184

Group type: EXPERIMENTAL
Intervention: Vascular closure device (VCD) used after PCI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no VCD) not explicitly mentioned
Number of subjects: 200
Study: 28209218

Group type: EXPERIMENTAL
Intervention: NOAC (non-vitamin K antagonist oral anticoagulants)
Number of subjects: 15641
Study: 28209559

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT), CEUS, and MRI
Number of subjects: 20
Study: 28209597

Group type: EXPERIMENTAL
Intervention: Cluster 1 (40%): Increased ankle eversion, external rotation, knee internal rotation, and greater knee work.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Cluster 2 (15%): Increased hip flexion, pelvis contralateral drop, thorax tilt, and increased hip work.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Cluster 3 (45%): High ankle dorsiflexion, thorax contralateral drop, ankle work, and prolonged ground contact time.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Overall findings: No correlation between movement clusters and clinically palpated location of pain.
Number of subjects: 322
Study: 28210662

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40)
Number of subjects: 0
Study: 28210927

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus peginterferon alfa-2a/ribavirin (PegIFN/RBV)
Number of subjects: 301
Study: 28211448

Group type: EXPERIMENTAL
Intervention: CX-5461
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CX-3543
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CX-5461 and CX-3543
Number of subjects: 0
Study: 28212292

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 407

Group type: COMPARATOR
Intervention: Conventional care regimens
Number of subjects: 407
Study: 28212686

Group type: EXPERIMENTAL
Intervention: simplified overweight screening instrument without BMI calculation
Number of subjects: 168

Group type: COMPARATOR
Intervention: 2007 World Health Organization Body Mass Index (BMI)-for-age reference Tables
Number of subjects: 168
Study: 28212684

Group type: EXPERIMENTAL
Intervention: RENAPE observational registry
Number of subjects: 0
Study: 28212993

Group type: EXPERIMENTAL
Intervention: gefitinib (250mg/day)
Number of subjects: 186

Group type: COMPARATOR
Intervention: carboplatin/paclitaxel
Number of subjects: 186
Study: 28213002

Group type: EXPERIMENTAL
Intervention: Dovitinib (500mg/day for 5 days on, 2 days off in 28-day cycles)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 12
Study: 28213204

Group type: EXPERIMENTAL
Intervention: Faster eating rates
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Children with overweight
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Eating behaviours
Number of subjects: 386